CTA comments on proposed guidance documents: “Artificial Intelligence Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations” and “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.”